Atrys Health SL (ATRY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Atrys Health SL (ATRY) has a cash flow conversion efficiency ratio of -0.031x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-4.67 Million ≈ $-5.46 Million USD) by net assets (€151.96 Million ≈ $177.65 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Atrys Health SL (ATRY) balance sheet quality index to measure how much of total assets are equity-financed.
Atrys Health SL - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Atrys Health SL's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Atrys Health SL earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Atrys Health SL Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Atrys Health SL ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
China Glaze Co Ltd
TW:1809
|
0.014x |
|
Gyldendal A/S
CO:GYLD-A
|
0.262x |
|
TBI Motion Technology Co Ltd
TW:4540
|
-0.091x |
|
CSG Holding Co Ltd
SHE:200012
|
0.023x |
|
Aekyung Industrial Co Ltd
KO:018250
|
-0.005x |
|
Imagesat International ISI Ltd
TA:ISI
|
0.108x |
|
Holiday Entertainment Co Ltd
TW:9943
|
0.043x |
|
Bin Chuan Enterprise Co Ltd
TWO:1569
|
-0.024x |
Annual Cash Flow Conversion Efficiency for Atrys Health SL (2015–2025)
The table below shows the annual cash flow conversion efficiency of Atrys Health SL from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see Atrys Health SL market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €151.96 Million ≈ $177.65 Million |
€-1.56 Million ≈ $-1.82 Million |
-0.010x | -186.69% |
| 2024-12-31 | €253.24 Million ≈ $296.07 Million |
€3.00 Million ≈ $3.50 Million |
0.012x | +413.87% |
| 2023-12-31 | €289.88 Million ≈ $338.90 Million |
€-1.09 Million ≈ $-1.28 Million |
-0.004x | +91.75% |
| 2022-12-31 | €337.57 Million ≈ $394.66 Million |
€-15.43 Million ≈ $-18.04 Million |
-0.046x | -366.86% |
| 2021-12-31 | €273.98 Million ≈ $320.31 Million |
€4.69 Million ≈ $5.49 Million |
0.017x | +192.45% |
| 2020-12-31 | €75.33 Million ≈ $88.07 Million |
€-1.40 Million ≈ $-1.63 Million |
-0.019x | -168.34% |
| 2019-12-31 | €39.95 Million ≈ $46.71 Million |
€1.08 Million ≈ $1.27 Million |
0.027x | +178.48% |
| 2018-12-31 | €26.44 Million ≈ $30.91 Million |
€-913.68K ≈ $-1.07 Million |
-0.035x | -161.14% |
| 2017-12-31 | €23.30 Million ≈ $27.24 Million |
€1.32 Million ≈ $1.54 Million |
0.057x | +201.57% |
| 2016-12-31 | €14.26 Million ≈ $16.68 Million |
€-793.63K ≈ $-927.84K |
-0.056x | -258.82% |
| 2015-12-31 | €11.70 Million ≈ $13.68 Million |
€409.89K ≈ $479.21K |
0.035x | -- |
About Atrys Health SL
Atrys Health, S.A., together with its subsidiaries, provides diagnostic services and medical treatments in Spain, Portugal, and Latin America. It operates through Diagnosis, Oncology, and Preventive Medicine segments. The company offers integrated diagnostics services comprising structural and molecular pathology, genetics, and nuclear medicine diagnosis; online medical imaging in the fields of r… Read more